In Vivo Selection ofPlasmodium falciparumParasites Carrying the Chloroquine-SusceptiblepfcrtK76 Allele after Treatment with Artemether-Lumefantrine in Africa
The Journal of Infectious Diseases2009Vol. 199(5), pp. 750–757
Citations Over TimeTop 1% of 2009 papers
Christin Sisowath, Ines Petersen, María Isabel Veiga, Andreas Mårtensson, Zul Premji, Anders Björkman, David A. Fidock, José Pedro Gil
Abstract
Our findings suggest that the pfcrt K76T mutation is a drug-specific contributor to enhanced P. falciparum susceptibility to lumefantrine in vivo and in vitro, and they highlight the benefit of using AL in areas affected by chloroquine-resistant P. falciparum malaria.
Related Papers
- → The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria(2006)118 cited
- → Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria(2015)30 cited
- → Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria(2018)19 cited
- → Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®)(2015)13 cited
- → Artemether-Lumefantrine: An Option for Malaria(2012)31 cited